The GLP-1 agonist liraglutide reduces excess fat accumulation in bone marrow of diabetic rats by suppressing miR-150-5p and upregulating GDF11, revealing a novel bone-protective mechanism beyond blood sugar control.
miR-150-5p/GDF11 axisnewly identified molecular pathway through which liraglutide reduces bone marrow fat — suppressing the microRNA that targets GDF11, a key inhibitor of adipogenesis
What the researchers found
Liraglutide reduces bone marrow fat accumulation in diabetic rats by suppressing miR-150-5p expression, which upregulates GDF11 — a novel mechanism explaining the peptide drug's bone-protective effects.
Why it matters
Diabetes significantly increases fracture risk, partly through excess bone marrow fat replacing healthy bone-forming tissue. Discovering that liraglutide — already widely prescribed for diabetes — protects bone marrow through a specific molecular pathway adds another reason to consider GLP-1 agonists for diabetic patients at risk of bone disease.
The numbers in context
HFD + STZ diabetic rat model; liraglutide treatment; miR-150-5p and GDF11 identified as key pathway mediators.
How the study worked
Diabetic rat model (HFD + STZ). High-throughput miRNA sequencing of BMSCs after liraglutide treatment identified differentially expressed miRNAs. Validated miR-150-5p/GDF11 axis using overexpression/knockdown studies in vitro (high-glucose BMSCs) and agomiR injection in vivo. Assessed bone marrow lipid accumulation histologically.
Who was studied
Diabetic rats (HFD + STZ model)
What this study cannot tell us
Animal study — human bone marrow response may differ. The HFD+STZ rat model is a simplified version of human type 2 diabetes. Only miR-150-5p was deeply characterized among the five changed miRNAs — the others may contribute. The study focused on adipogenesis but didn't assess bone density or fracture outcomes. Liraglutide dosing in rats may not correspond to human doses.
How to read the evidence
Preliminary — animal study with in vitro validation identifying a molecular mechanism. No human bone marrow or fracture data.
When this study was published
Published in 2024, adding to the growing evidence of GLP-1 agonist benefits beyond glycemic control.
The bigger picture
GLP-1 agonists continue to reveal benefits beyond glucose control — cardiovascular protection, weight loss, kidney protection, and now bone marrow fat reduction. This study adds mechanistic depth by identifying the miR-150-5p/GDF11 axis, suggesting that GLP-1 signaling influences epigenetic regulators (microRNAs) that control stem cell fate decisions in bone marrow. This could inform development of targeted therapies for diabetic bone disease.
Questions still open
- Does liraglutide's bone marrow fat reduction translate to reduced fracture risk in diabetic patients?
- Do other GLP-1 agonists (semaglutide, tirzepatide) show the same miR-150-5p/GDF11-mediated bone protection?
- Could targeting miR-150-5p directly provide bone protection without needing a GLP-1 agonist?
Common questions
Why does diabetes cause fat to build up in bone marrow?
Could liraglutide help prevent fractures in people with diabetes?
Read the original research
Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.
European journal of pharmacology, 978, 176793
Citation
Wang, Na; Lin, Zhe; Gao, Liu; Wang, Bin; Wei, Kangxu; Zhang, Menghan; Li, Yukun; Xue, Peng. (2024). Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.. European journal of pharmacology, 978, 176793. https://doi.org/10.1016/j.ejphar.2024.176793